These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Multiple myeloma].
    Author: Abe M.
    Journal: Nihon Rinsho; 2009 May; 67(5):991-5. PubMed ID: 19432122.
    Abstract:
    Multiple myeloma causes debilitating clinical symptoms including intractable bone pain, disabling multiple fractures and hypercalcemia. Bisphosphonates, potent inhibitors of osteoclast-mediated bone destruction, prevent skeletal-related events in myeloma. However, the impact of long-term bisphosphonate use remains unclear because of insufficient follow-up, while osteonecrosis of the jaw (ONJ) emerges as a major concern. The proteosome inhibitor bortezomib is a novel anti-myeloma agent, which has been recently drawn a considerable attention in its anabolic effects to resume bone formation in patients with myeloma. It is important to clarify the roles of these bone-targeting agents in the treatment for a myeloma bone disease and make the best use of them by eliminating underlying risk of their adverse effects.
    [Abstract] [Full Text] [Related] [New Search]